ZBP1 and neoplasm: Studies indicate that ZBP1 expression is typically low in tumors characterized by genomic instability, such as triple‐negative breast cancer, which leads to enhanced oxidative stress tolerance and inadequate immune response, further complicating treatment.[25] Upregulating ZBP1 expression can effectively increase tumor cell sensitivity to ROS, activate its downstream cell death pathways, and thereby improving therapeutic efficacy.